KYTXHealthcare · BiotechnologyThe 6 Wall Street analysts covering Kyverna Therapeutics, Inc. hold a median 12-month price target of $32 — +332.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Kyverna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (84): The shares have been drifting up relative to others.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KYTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +332.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 May 2026 | JP Morgan | Maintains | Overweight | — |
| 23 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 4 Dec 2025 | Morgan Stanley | Maintains | Overweight | — |
| 30 Oct 2025 | Wells Fargo | Maintains | Overweight | — |
| 27 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Oct 2025 | Wells Fargo | Maintains | Overweight | — |
| 29 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Aug 2025 | William Blair | Initiates | Outperform | — |
| 27 May 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 1 Apr 2025 | Morgan Stanley | Maintains | Overweight | — |
| 20 Nov 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 15 Nov 2024 | Wells Fargo | Maintains | Overweight | — |
| 10 Oct 2024 | UBS | Initiates | Buy | — |
| 19 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Aug 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 31 July 2024 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KYTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, Kyverna Therapeutics, Inc. returned +88.8% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 36% of US stocks
Cheaper than 71% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 15% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kyverna Therapeutics, Inc. has a market value of $449.0M and an enterprise value of $282.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$152.6M.
Diluted earnings per share, trailing twelve months: $−2.94.
Free cash flow in the twelve months to 30 June 2026: −$160.2M.
Trailing P/E: −2.0×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Kyverna Therapeutics, Inc. employs 149 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kyverna Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kyverna Therapeutics announced that its management will present at upcoming investor conferences. The company is a late-stage clinical immunology firm focused on therapies for neurologic autoimmune diseases.
Why it matters — The conference presentations offer investors and analysts an opportunity to hear directly from Kyverna's management about its pipeline and business.
Kyverna Therapeutics is advancing mivocabtagene autoleucel for autoimmune diseases, with a rolling BLA submission underway targeting completion in late 2026 and potential approval by mid-2027. Updated KYSA-8 data showed all 26 patients remained off chronic immunotherapies at 16 weeks with 81% mobility improvement, and key phase 2/3 data in myasthenia gravis are expected soon.
Why it matters — For KYTX watchers, this item highlights regulatory and clinical momentum toward a first approval in stiff person syndrome, with upcoming myasthenia gravis data representing a near-term catalyst.
Kyverna Therapeutics reported pipeline progress and second quarter 2026 financial results. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS), based on compelling clinical data, expanding the therapy's potential across neuroimmunology.
Why it matters — The RMAT designation for miv-cel in naSPMS signals regulatory recognition of the therapy's clinical data and broadens Kyverna's pipeline opportunity in neuroimmunology.
Kyverna Therapeutics is described as a 'Strong Buy' as its candidate miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. A rolling BLA submission for miv-cel in SPS is underway targeting completion by Q4 2026, and a manufacturing agreement with ElevateBio has been secured to support commercialization.
Why it matters — KYTX watchers would care because the ElevateBio manufacturing deal supports supply for miv-cel's potential U.S. and global commercialization, while the rolling BLA submission marks a key regulatory milestone for the pipeline.
Kyverna Therapeutics entered into a commercial manufacturing and supply agreement with ElevateBio for its therapy Miv-cel.
Why it matters — The agreement establishes a commercial supply chain for Miv-cel, signaling progress toward potential manufacturing readiness for Kyverna's pipeline.
The 6 Wall Street analysts covering Kyverna Therapeutics, Inc. have a median 12-month price target of $32, with estimates ranging from $25 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Kyverna Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyverna Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Kyverna Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +332.4% from the last close, and Ticker Nerd's factor model ranks Kyverna Therapeutics, Inc. 41 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kyverna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $33 over the next 12 months.
Kyverna Therapeutics, Inc. returned +88.8% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases.
The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Kyverna Therapeutics to Present at Upcoming Investor Conferences". Kyverna Therapeutics announced that its management will present at upcoming investor conferences. The company is a late-stage clinical immunology firm focused on therapies for neurologic autoimmune diseases.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company’s work centers on engineered T-cell therapies, including CAR T-cell and related cell therapy approaches designed to target the immune cells that drive severe autoimmune and inflammatory conditions. Its current programs span multiple therapeutic areas, with particular emphasis on rheumatology and neurology, alongside research efforts in other antibody-mediated and inflammatory diseases. Kyverna Therapeutics develops product candidates for conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, stiff person syndrome, multiple sclerosis, and inflammatory bowel disease. The company’s platform combines advanced cell engineering and synthetic biology to pursue more precise immune modulation than traditional broad immunosuppressive treatments. Headquartered in Emeryville, California, Kyverna Therapeutics plays a specialized role in the biotechnology market by advancing cell-based immunology therapies for serious unmet medical needs.
CEO Mr. Warner Biddle · 149 employees · United States · https://kyvernatx.com
